Skip to Main Navigation
Skip to Page Content
Share This:
https://ntp.niehs.nih.gov/go/17759

TDMS Study 93021-06 Pathology Tables

NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01
Route: SKIN APPLICATION                                                                                           Time: 09:20:54

                                                         Final #1/Mice




       Facility:  BIORELIANCE

       Chemical CAS #:  538-75-0

       Lock Date:  02/24/00

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01    
Route: SKIN APPLICATION                                                                                           Time: 09:20:54    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                                                        2                         7           
    Natural Death                                                                             1            1            1           
  Survivors                                                                                                                         
    Terminal Sacrifice                                15           15           15           12           14            7           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (14)         (15)         
      Hematopoietic Cell Proliferation                                                                                  1 (7%)      
      Hematopoietic Cell Proliferation, Focal                                                                           1 (7%)      
      Infiltration Cellular, Focal, Lymphocyte                      1 (7%)                    4 (27%)      1 (7%)       2 (13%)     
      Inflammation, Chronic Active, Focal                                                                               1 (7%)      
      Hepatocyte, Necrosis, Focal                      4 (27%)      6 (40%)      5 (33%)      4 (27%)      2 (14%)      1 (7%)      
      Periportal, Vacuolization Cytoplasmic, Focal                                            1 (7%)                                
   Stomach, Glandular                                 (15)         (15)         (15)         (15)         (14)         (14)         
      Infiltration Cellular, Focal, Lymphocyte                                                1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (15)         (14)         (13)         
      Subcapsular, Hyperplasia                                                                                          1 (8%)      
      Subcapsular, Hyperplasia, Focal                 13 (87%)     13 (87%)     12 (80%)     13 (87%)     14 (100%)     9 (69%)     
   Thyroid Gland                                      (13)         (15)         (15)         (14)         (13)         (13)         
      Ectopic Thymus                                                2 (13%)      3 (20%)      1 (7%)       1 (8%)                   
      Inflammation, Chronic Active, Focal              1 (8%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01    
Route: SKIN APPLICATION                                                                                           Time: 09:20:54    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (14)         (14)         
      Atrophy                                                                    1 (7%)                                 1 (7%)      
   Uterus                                             (15)         (15)         (15)         (15)         (14)         (14)         
      Endometrium, Hyperplasia, Cystic                14 (93%)     15 (100%)    15 (100%)    13 (87%)     13 (93%)      7 (50%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (15)         (15)         (15)         (15)         (14)         (15)         
      Myeloid Cell, Hyperplasia                                                               3 (20%)      1 (7%)       8 (53%)     
   Lymph Node                                                                                (1)                                    
      Inguinal, Hyperplasia, Lymphoid                                                         1 (100%)                              
   Lymph Node, Mandibular                             (15)         (15)         (14)         (14)         (14)         (14)         
      Hyperplasia, Lymphoid                            1 (7%)                                 2 (14%)      3 (21%)                  
   Lymph Node, Mediastinal                            (14)         (15)         (15)         (12)         (13)         (13)         
      Hyperplasia, Lymphoid                                                      1 (7%)                                             
   Spleen                                             (15)         (15)         (15)         (15)         (14)         (14)         
      Hematopoietic Cell Proliferation                15 (100%)    15 (100%)    15 (100%)    15 (100%)    13 (93%)     13 (93%)     
      Pigmentation                                                                                                      1 (7%)      
   Thymus                                             (15)         (15)         (15)         (15)         (14)         (13)         
      Atrophy, Diffuse                                                                                                  2 (15%)     
      Atrophy, Focal                                                2 (13%)      1 (7%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (15)         (15)         (15)         (15)         (14)         (14)         
      Inflammation, Chronic Active, Focal                                                                               1 (7%)      
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Control, Ulcer, Focal                                                                   1 (7%)                    2 (13%)     
      Dermis, Epidermis, Hyperplasia, Focal                                                                             1 (7%)      
      Dermis, Control, Inflammation, Chronic                                                                                        
          Active, Focal                                                                       3 (20%)      1 (7%)       2 (13%)     
      Dermis, Skin, Site of Application, Fibrosis                                                                       1 (7%)      
      Dermis, Skin, Site of Application,                                                                                            
          Inflammation, Chronic Active, Focal          1 (7%)                                13 (87%)      2 (13%)      9 (60%)     
      Epidermis, Control, Hyperplasia, Focal                                                  2 (13%)                   1 (7%)      
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia, Diffuse                                                   1 (7%)       2 (13%)                               
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia, Focal                                        1 (7%)       5 (33%)     11 (73%)      1 (7%)       8 (53%)     
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01    
Route: SKIN APPLICATION                                                                                           Time: 09:20:54    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
INTEGUMENTARY SYSTEM - CONT                                                                                                         
      Sebaceous Gland, Control, Hyperplasia, Focal                                            1 (7%)                    1 (7%)      
      Sebaceous Gland, Skin, Site of Application,                                                                                   
           Hyperplasia, Focal                                                                 3 (20%)                   3 (20%)     
      Skin, Site of Application, Hyperkeratosis,                                                                                    
           Diffuse                                                                            1 (7%)       1 (7%)                   
      Skin, Site of Application, Parakeratosis,                                                                                     
           Focal                                                                              1 (7%)       1 (7%)                   
      Skin, Site of Application, Ulcer, Focal                                                 2 (13%)      1 (7%)       8 (53%)     
      Subcutaneous Tissue, Control, Inflammation,                                                                                   
           Chronic Active, Focal                                                              1 (7%)                    2 (13%)     
      Subcutaneous Tissue, Skin, Site of                                                                                            
          Application, Inflammation, Chronic, Focal                                                        1 (7%)                   
      Subcutaneous Tissue, Skin, Site of                                                                                            
          Application, Inflammation, Chronic                                                                                        
          Active, Focal                                                                       2 (13%)                   8 (53%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (14)         (15)         
      Alveolar Epithelium, Hyperplasia, Focal                                    1 (7%)                                             
      Alveolar Epithelium, Inflammation, Chronic                                                                                    
          Active, Focal                                             1 (7%)                                                          
      Alveolus, Inflammation, Chronic Active, Focal    1 (7%)                                              1 (7%)       1 (7%)      
      Perivascular, Infiltration Cellular, Focal,                                                                                   
           Lymphocyte                                  1 (7%)                                              2 (14%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01    
Route: SKIN APPLICATION                                                                                           Time: 09:20:54    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (14)         (14)         
      Infiltration Cellular, Focal, Lymphocyte                      1 (7%)                                                          
      Pelvis, Infiltration Cellular, Focal,                                                                                         
          Lymphocyte                                                                          1 (7%)                                
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------